Rupatadine and levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety

Journal of Drugs in Dermatology

Volumn 10, Issue 12, 2011, Pages 1444-1450

  Maiti, Rituparna ^a   Jaida, Jyothirmai ^a   Raghavendra, B N ^a   Goud, Prakash ^a   Ahmed, Idris ^a   Palani, Anuradha ^a  

^a Prathima Institute of Medical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; LEVOCETIRIZINE; RUPATADINE;

ADOLESCENT; ADULT; AERIUS QUALITY OF LIFE QUESTIONNAIRE SCORE; ARTICLE; CHRONIC IDIOPATHIC URTICARIA; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; GLOBAL EFFICACY SCORE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; STOMACH IRRITATION; TOTAL SYMPTOM SCORE; URTICARIA; XEROSTOMIA;

ADOLESCENT; ADULT; CETIRIZINE; CHILD; CHRONIC DISEASE; CYPROHEPTADINE; FEMALE; FOLLOW-UP STUDIES; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

EID: 84055199733     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Nettis E, Pannofino A, D'Aprile C, Ferrannini A, Tursi A. Clinical and aetiological aspects in urticaria and angioedema. Br J Dermatol. 2003;148:501-506. (Pubitemid 36461329)
2. Sudha Yadav, Amitabh Upadhyay, AK Bajaj. Chronic urticaria: An overview. Indian J Dermatol. 2006;51(3):171-177.
3. Zuberbier T, Maurer. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol. 2007;87(3):196-205. (Pubitemid 47226886)
4. Advenier C. and Roussel Q.C. Rational use of antihistamines in allergic dermatological conditions. Drugs. 1989;38:634-644. (Pubitemid 19258565)
5. Shiekh J. Advances in the treatment of chronic urticaria. Immunol Allergy Clin North Am. 2004;24:317-334.
6. Hennino A, Bérard F, Guillot I, Saad N, Rozières A, Nicolas JF. Pathophysiology of urticaria. Clin Rev Allergy Immunol. 2006;30(1):3-11. (Pubitemid 43199216)
7. Ring J, Brockow K, Ollert M, Engst R. Antihistamines in urticaria. Clin Exp Allergy. 1999;29:31-37. (Pubitemid 29145152)
8. Black AK, Champion RH. Urticaria. In Champion RH, Burton JL, Burns DA, et al., eds. Textbook of Dermatology, 6th ed. Oxford, England: Blackwell Science, 1998:2113-2139.
9. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol. 2006;45(4):469-474.
10. Kapp A, Wedi B. Chronic urticaria: Clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol. 2004;3(6):632-639.
11. Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A. Levocetirizine in the treatment of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006;154:533-538.
12. Pfaar O, Wrede H, Barth C, Hansen I, Klimek L. Levocetirizine in patients with chronic idiopathic urticaria: results of a multicenter clinical practice study. Int J Clin Pharmacol Ther. 2006;44(4):191-192.
13. Walsh GM. Levocetirizine: An update. Curr Med Chem. 2006;13(22):2711- 2715. (Pubitemid 44364148)
14. Arnaiz E, Zalupca L, Cristodoulo T, et al. Efficacy and safety of rupatadine 5, 10 and 20 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled, dose finding trial. Allergy Clin Immunol Int. 2005;(suppl 1):242-243.
15. Gimenez-Arnau A, Pujol R M, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy. 2007;62(5):539-546. (Pubitemid 46608361)
16. César P. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006;7(14):1989-2001.
17. Caproni M, Volpi W, Giomi B, Torchia D, Del Bianco E, Fabbri P. Cellular adhesion molecules in chronic urticaria: Modulation of serum levels occurs during Levocetirizine treatment. Br J Dermatol. 2006;155(6):1270-1274. (Pubitemid 44730006)
18. Wu P, Mitchell S, Walsh GM. A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. Clin Exp Allergy. 2005;35(8):1073-1079. (Pubitemid 41603142)
19. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004;18(4):399-411. (Pubitemid 39215352)
20. Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy. 2001;56(10):985-988. (Pubitemid 32835604)
21. Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66(7):973-996. (Pubitemid 43853006)
22. Popov TA, Dumitrascu D, Bachvarova A, Bocsan C, Dimitrov V, Church MK. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res. 2006;55(6):241-244. (Pubitemid 44359138)
23. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216. (Pubitemid 24194579)
24. Harold Kim,Charles Lynde. Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study. Arch Drug Info. 2008;1:63-69.
25. Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA. Comparison of the risk of drowsiness and sedation between Levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 2006;29(10):897-909. (Pubitemid 44511590)
26. Hwang SB, Li CL, Lam MH, Shen TY. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Lab Invest. 1985;52:617-630. (Pubitemid 15037046)
27. Sansom JE, Brooks J, Burton JL, Archer CB. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin. Clin Exp Dermatol. 1996;21:33-37. (Pubitemid 26167417)
28. Jenks PJ, Kavanagh GM, Brooks J, Bradfield JW, Archer CB. Comparison of the wheal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Clin Exp Dermatol. 1999;24:112-117. (Pubitemid 29223020)
29. Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. 2007;17(3):223-228. (Pubitemid 46847786)
30. Petersen LJ, Church MK, Skov PS. Platelet-activating factor induces histamine release from human mast cells in vivo, which is reduced by local nerve blockade. J Allergy Clin Immunol. 1997;99:640-647. (Pubitemid 27213192)
31. Prescott SM, Zimmerman GA, McIntyre TM. The production of platelet-activating factor by cultured human endothelial cells: regulation and function. In: Snyder F, ed. Platelet activating factor and related lipid mediators. New York: Plenum Press, 1987:323-340.
32. Roumestan C, Henriquet C, Mathieu M, Bousquet J: Effects of rupatadine on inflammatory mediators and transcription factors: a comparison with desloratadine and levocetirizine. Allergy Clin Immunol Int. 2005;(suppl. 1):450.
33. Barrón S, Ramis I, García-Rafanell J, Merlos M. Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity. Methods Find Clin Pharmacol. 2005;27(suppl 2):161.